Additional Items Review Sample Clauses

Additional Items Review. The IRO shall review up to five additional areas or practices (Additional Items) of the Friendship Entities identified by OIG in its sole discretion. 1. For purposes of identifying the Additional Items to be included in the Additional Items Review for a particular IRO Reporting Period, OIG may consider: (1) proposals submitted by the Friendship Entities or the IRO at least 120 days prior to the end of each Reporting Period; (2) internal risk assessment, audit, and monitoring work conducted by the Friendship Entities or the IRO; and (3) other information known to OIG. 2. The Friendship Entities may propose to OIG that their internal audit(s) be partially substituted for one or more of the Additional Items that would otherwise be reviewed by the IRO as part of the Additional Items Review. OIG retains sole discretion over whether, and in what manner, to allow the Friendship Entities’ internal audit work to be substituted for a portion of the Additional Items Review conducted by the IRO. 3. OIG shall notify the Friendship Entities and the IRO of the nature and scope of the IRO review for each of the Additional Items in the Additional Items Review at least 90 days prior to the end of each Reporting Period. Prior to undertaking the review of the Additional Items, the IRO and/or the Friendship Entities shall submit an audit work plan to OIG for approval and the IRO shall conduct the review of the Additional Items based on a work plan approved by OIG.

Additional Items Review. In addition to the Claims Review, the IRO shall review up to five additional areas or practices of the Friendship Entities identified by OIG in its discretion (Additional Items Review) and shall prepare an Additional Items Review Report, as outlined in Appendix B to this CIA, which is incorporated by reference.

Additional Items Review. Each IRO review shall also include a review of up to three additional areas or practices of RMS identified by OIG in its discretion (hereafter “Additional Items”). For purposes of identifying the Additional Items to be included in the IRO review for a particular Reporting Period, OIG will consult with RMS and may consider internal audit and monitoring work conducted by RMS, the Government Reimbursed Product portfolio, the nature and scope of RMS’s promotional and other practices, the nature and scope of RMS’s arrangements with HCPs and HCIs, and other information known to OIG.

Additional Items Review. In addition to the Government Pricing Functions Review, OIG may, in its discretion, require a review by the IRO of up to three additional areas or practices of Mylan identified by OIG relating to Government Pricing Functions (hereafter “Additional Items”) and prepare an Additional Items Review Report, as outlined in Appendix B.

Additional Items Review. Each IRO review shall also include a review of up to three additional areas or practices of Insys identified by OIG in its discretion (hereafter “Additional Items”). For purposes of identifying the Additional Items to be included in the IRO review for a particular Reporting Period, OIG will consult with Insys and may consider internal audit and monitoring work conducted by Insys, the Government Reimbursed Product portfolio, the nature and scope of Insys’s promotional practices and arrangements with HCPs and HCIs, and other information known to it.‌

Additional Items Review. In addition to the Arrangements Review, during the five years of the CIA, the IRO may be asked by OIG to review up to a total of five additional areas or practices of ION identified by OIG in its discretion (“Additional Items Review”) and shall prepare an Additional Items Review Report, as outlined in Appendix B to this CIA, which is incorporated by reference.

Additional Items Review. Each IRO review shall also include a review of up to three additional areas or practices of Novartis identified by OIG in its discretion (hereafter “Additional Items”). For purposes of identifying the Additional Items to be included in the IRO review for a particular Reporting Period, OIG will consult with Novartis and may consider internal audit and monitoring work conducted by Novartis, the Government Reimbursed Product portfolio, the nature and scope of Novartis’ promotional practices and arrangements with HCPs and HCIs, and other information known to it.

Additional Items Review. For each Reporting Period, OIG, in its discretion, may identify up to three additional areas or practices of Mallinckrodt for the IRO to include in its Transaction Review (hereinafter “Additional Items”). For purposes of identifying the Additional Items to be included in the Transactions Review for a particular Reporting Period, OIG will consult with Mallinckrodt and may consider internal audit and monitoring work conducted by Mallinckrodt, the Government Reimbursed Product portfolio, the nature and scope of Mallinckrodt’s promotional practices and arrangements with health care professionals and health care institutions, and other information known to it.

Additional Items Review. Each IRO review shall also include a review of up to three additional areas or practices of Essilor identified by OIG in its discretion (hereafter “Additional Items”). For purposes of identifying the Additional Items to be included in the IRO review for a particular Reporting Period, OIG will consult with Essilor and may consider internal audit and monitoring work conducted by ▇▇▇▇▇▇▇, the Government Reimbursed Product portfolio, the nature and scope of Essilor’s promotional and other practices, the nature and scope of Essilor’s arrangements with ECPs and ECIs, and other information known to OIG.